Medigen Vaccine Biologics (6547) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 高端疫苗

Medigen Vaccine Biologics (6547) reported revenue of NT$100 million for Oct 2026, +43.2% year on year and -51.7% from the previous month. Revenue for Jan–Oct 2026 was NT$811.9 million (+51.5% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 73 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$56.3 million24/10Nov 2024 NT$35.5 millionDec 2024 NT$37 millionJan 2025 NT$36 millionFeb 2025 NT$33.8 million25/02Mar 2025 NT$45.6 millionApr 2025 NT$42 millionMay 2025 NT$46.4 millionJun 2025 NT$56.5 million25/06Jul 2025 NT$55.9 millionAug 2025 NT$45.7 millionSep 2025 NT$104.2 millionOct 2025 NT$69.8 million25/10Nov 2025 NT$34.8 millionDec 2025 NT$42.4 millionJan 2026 NT$37.1 millionFeb 2026 NT$25.3 million26/02Mar 2026 NT$43.5 millionApr 2026 NT$38.7 millionMay 2026 NT$34.8 millionJun 2026 NT$41.6 million26/06Jul 2026 NT$47.4 millionAug 2026 NT$236.4 millionSep 2026 NT$207.2 millionOct 2026 NT$100 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$100 million+43.2%-51.7%
Sep 2026NT$207.2 million+98.8%-12.4%
Aug 2026NT$236.4 million+416.9%+399.0%
Jul 2026NT$47.4 million-15.3%+14.0%
Jun 2026NT$41.6 million-26.4%+19.5%
May 2026NT$34.8 million-25.0%-10.2%
Apr 2026NT$38.7 million-7.9%-11.0%
Mar 2026NT$43.5 million-4.6%+72.0%
Feb 2026NT$25.3 million-25.2%-31.8%
Jan 2026NT$37.1 million+3.2%-12.5%
Dec 2025NT$42.4 million+14.5%+21.6%
Nov 2025NT$34.8 million-1.8%-50.1%
Oct 2025NT$69.8 million+23.9%-33.0%
Sep 2025NT$104.2 million-14.9%+127.8%
Aug 2025NT$45.7 million-17.6%-18.2%
Jul 2025NT$55.9 million-14.0%-1.0%
Jun 2025NT$56.5 million+12.4%+21.8%
May 2025NT$46.4 million-44.8%+10.4%
Apr 2025NT$42 million+2.5%-7.9%
Mar 2025NT$45.6 million+73.1%+35.0%
Feb 2025NT$33.8 million+140.7%-6.0%
Jan 2025NT$36 million+97.8%-2.8%
Dec 2024NT$37 million+57.3%+4.3%
Nov 2024NT$35.5 million-43.8%-37.0%
Oct 2024NT$56.3 million-33.4%-54.0%

Jan–Oct 2026 cumulative: NT$811.9 million (+51.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Medigen Vaccine Biologics vs PEC / Medigen Vaccine Biologics vs Lotus Pharm / Medigen Vaccine Biologics vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本期增加海外營收

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16